Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 Tan CAR T Cells in Relapsed/Refractory B-cell Malignancies
NCT03185494Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of tanCART-19/22 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
tanCART-19/22
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03185494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185494.